XIN Stock Overview
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Shandong Xinhua Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.62 |
| 52 Week High | HK$0.78 |
| 52 Week Low | HK$0.55 |
| Beta | -0.011 |
| 1 Month Change | 2.48% |
| 3 Month Change | 2.48% |
| 1 Year Change | -20.00% |
| 3 Year Change | 30.80% |
| 5 Year Change | 36.26% |
| Change since IPO | 795.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| XIN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.6% | 2.3% | 0.5% |
| 1Y | -20.0% | -28.6% | 1.3% |
Return vs Industry: XIN exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: XIN underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| XIN volatility | |
|---|---|
| XIN Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XIN has not had significant price volatility in the past 3 months.
Volatility Over Time: XIN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 7,104 | n/a | www.xhzy.com |
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic drugs; cardiovascular and cerebrovascular drugs; anti-infective drugs and central nervous drugs; and other drugs. It engages in the development of real estate business.
Shandong Xinhua Pharmaceutical Company Limited Fundamentals Summary
| XIN fundamental statistics | |
|---|---|
| Market cap | €1.11b |
| Earnings (TTM) | €63.94m |
| Revenue (TTM) | €1.04b |
6.9x
P/E Ratio0.4x
P/S RatioIs XIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XIN income statement (TTM) | |
|---|---|
| Revenue | CN¥8.10b |
| Cost of Revenue | CN¥5.78b |
| Gross Profit | CN¥2.32b |
| Other Expenses | CN¥1.82b |
| Earnings | CN¥496.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 0.73 |
| Gross Margin | 28.66% |
| Net Profit Margin | 6.13% |
| Debt/Equity Ratio | 28.4% |
How did XIN perform over the long term?
See historical performance and comparison